| RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth G Hatzivassiliou, K Song, I Yen, BJ Brandhuber, DJ Anderson, R Alvarado, ... Nature 464 (7287), 431-435, 2010 | 1805 | 2010 |
| Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 TT Junttila, RW Akita, K Parsons, C Fields, GDL Phillips, LS Friedman, ... Cancer cell 15 (5), 429-440, 2009 | 966 | 2009 |
| Systematic generation of high-resolution deletion coverage of the Drosophila melanogaster genome AL Parks, KR Cook, M Belvin, NA Dompe, R Fawcett, K Huppert, LR Tan, ... Nature genetics 36 (3), 288-292, 2004 | 884 | 2004 |
| The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective … AJ Folkes, K Ahmadi, WK Alderton, S Alix, SJ Baker, G Box, ... Journal of medicinal chemistry 51 (18), 5522-5532, 2008 | 848 | 2008 |
| Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families LS Friedman, EA Ostermeyer, CI Szabo, P Dowd, ED Lynch, SE Rowell, ... Nature genetics 8 (4), 399-404, 1994 | 828 | 1994 |
| Involvement of Brca2 in DNA repair KJ Patel, PCC Veronica, H Lee, A Corcoran, FC Thistlethwaite, MJ Evans, ... Molecular cell 1 (3), 347-357, 1998 | 801 | 1998 |
| A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene: implications for presymptomatic testing and screening D Shattuck-Eidens, M McClure, J Simard, F Labrie, S Narod, F Couch, ... Jama 273 (7), 535-541, 1995 | 596 | 1995 |
| In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models KP Hoeflich, C O'Brien, Z Boyd, G Cavet, S Guerrero, K Jung, T Januario, ... Clinical Cancer Research 15 (14), 4649-4664, 2009 | 584 | 2009 |
| Inactivation of PI (3) K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer K Ali, DR Soond, R Pineiro, T Hagemann, W Pearce, EL Lim, H Bouabe, ... Nature 510 (7505), 407-411, 2014 | 533 | 2014 |
| Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents M Degtyarev, A De Mazière, C Orr, J Lin, BB Lee, JY Tien, WW Prior, ... The Journal of cell biology 183 (1), 101-116, 2008 | 488 | 2008 |
| Drosophila p53 is a structural and functional homolog of the tumor suppressor p53 M Ollmann, LM Young, CJ Di Como, F Karim, M Belvin, S Robertson, ... Cell 101 (1), 91-101, 2000 | 480 | 2000 |
| Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. LS Friedman, SA Gayther, T Kurosaki, D Gordon, B Noble, G Casey, ... American journal of human genetics 60 (2), 313, 1997 | 364 | 1997 |
| Closing in on a breast cancer gene on chromosome 17q. JM Hall, L Friedman, C Guenther, MK Lee, JL Weber, DM Black, MC King American journal of human genetics 50 (6), 1235, 1992 | 341 | 1992 |
| Mechanism of MEK inhibition determines efficacy in mutant KRAS-versus BRAF-driven cancers G Hatzivassiliou, JR Haling, H Chen, K Song, S Price, R Heald, ... Nature 501 (7466), 232-236, 2013 | 327 | 2013 |
| Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. SL Neuhausen, S Mazoyer, L Friedman, M Stratton, K Offit, A Caligo, ... American journal of human genetics 58 (2), 271, 1996 | 312 | 1996 |
| First-in-human phase I study of pictilisib (GDC-0941), a potent pan–class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors D Sarker, JE Ang, R Baird, R Kristeleit, K Shah, V Moreno, PA Clarke, ... Clinical cancer research 21 (1), 77-86, 2015 | 311 | 2015 |
| Predictive biomarkers of sensitivity to the phosphatidylinositol 3′ kinase inhibitor GDC-0941 in breast cancer preclinical models C O'Brien, JJ Wallin, D Sampath, D GuhaThakurta, H Savage, ... Clinical cancer research 16 (14), 3670-3683, 2010 | 301 | 2010 |
| Identifying genotype-dependent efficacy of single and combined PI3K-and MAPK-pathway inhibition in cancer ML Sos, S Fischer, R Ullrich, M Peifer, JM Heuckmann, M Koker, ... Proceedings of the National Academy of Sciences 106 (43), 18351-18356, 2009 | 296 | 2009 |
| GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway JJ Wallin, KA Edgar, J Guan, M Berry, WW Prior, L Lee, JD Lesnick, ... Molecular cancer therapeutics 10 (12), 2426-2436, 2011 | 290 | 2011 |
| Mutation Analysis of the BRCA1 Gene in Ovarian Cancers H Takahashi, K Behbakht, PE McGovern, HC Chiu, FJ Couch, BL Weber, ... Cancer research 55 (14), 2998-3002, 1995 | 289 | 1995 |
